Context Therapeutics Inc. (NASDAQ:CNTX) Receives $5.40 Average Target Price from Brokerages

Context Therapeutics Inc. (NASDAQ:CNTX) has received an average recommendation of “Moderate Buy” from the nine research firms that are covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $5.40.

CNTX has been the subject of several recent research reports. Guggenheim began coverage on shares of Context Therapeutics in a research note on Thursday, September 18th. They set a “buy” rating and a $5.00 target price for the company. Cantor Fitzgerald initiated coverage on shares of Context Therapeutics in a report on Thursday, October 2nd. They issued an “overweight” rating for the company. Wall Street Zen raised shares of Context Therapeutics to a “sell” rating in a research report on Saturday. HC Wainwright raised their target price on shares of Context Therapeutics from $4.00 to $5.00 and gave the stock a “buy” rating in a report on Thursday, November 6th. Finally, D. Boral Capital restated a “buy” rating and issued a $9.00 target price on shares of Context Therapeutics in a research note on Thursday, November 6th.

Context Therapeutics Stock Down 2.6%

Shares of NASDAQ CNTX opened at $1.12 on Friday. The stock’s 50 day moving average price is $1.14 and its two-hundred day moving average price is $0.88. Context Therapeutics has a 52-week low of $0.49 and a 52-week high of $1.65. The stock has a market capitalization of $102.91 million, a P/E ratio of -4.67 and a beta of 1.94.

Context Therapeutics (NASDAQ:CNTX) last issued its earnings results on Wednesday, November 5th. The company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.09) by ($0.01). On average, analysts anticipate that Context Therapeutics will post -0.51 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in CNTX. Vanguard Group Inc. increased its position in Context Therapeutics by 4.0% in the third quarter. Vanguard Group Inc. now owns 3,495,031 shares of the company’s stock worth $3,387,000 after buying an additional 134,449 shares during the period. Citadel Advisors LLC acquired a new position in shares of Context Therapeutics during the third quarter valued at $100,000. Finally, Clear Harbor Asset Management LLC grew its position in shares of Context Therapeutics by 60.5% during the third quarter. Clear Harbor Asset Management LLC now owns 92,804 shares of the company’s stock worth $90,000 after acquiring an additional 35,000 shares during the last quarter. 14.03% of the stock is currently owned by institutional investors.

Context Therapeutics Company Profile

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.